Novo Nordisk drove Denmark's GDP growth in Q3 with a 2.3% quarterly increase mainly due to strong pharmaceutical exports.The company's reduced US drug prices followed a deal with the Trump administration, while its stock fell 49% YTD amid competition and restructuring under CEO Mike Doustdar.